5 results match your criteria: "Jewish General Hospital Stroll Cancer Prevention Centre[Affiliation]"
Best practice & research clinical haematology: Screening for breast cancer in hodgkin lymphoma survivors.
Best Pract Res Clin Haematol
December 2023
Department of Surgery and Oncology, McGill University Medical School, Montreal, QC, Canada; Jewish General Hospital Stroll Cancer Prevention Centre, Montreal, QC, Canada. Electronic address:
Childhood and young adult survivors of Hodgkin lymphoma are at an elevated risk of developing breast cancer. Breast cancer risk is felt to originate from chest wall radiation exposure prior to the third decade of life, with incidence beginning to rise approximately eight to ten years following Hodgkin lymphoma treatment. Although incidence varies according to age at radiation exposure, dosage, and treatment fields, cohort studies have documented a cumulative incidence of breast cancer of 10-20% by 40 years of age.
View Article and Find Full Text PDFCurrent and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy.
Am J Hum Genet
October 2023
Ontario Institute for Cancer Research, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Sinai Health System, Toronto, ON, Canada; Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address:
Article Synopsis
- At least 5% of cancer diagnoses are linked to hereditary cancer syndromes (HCS), leading to lifelong monitoring and anxiety for those affected.
- The CHARM Consortium was established in 2017 by genetics centers in Canada to explore the clinical validity of cell-free DNA (cfDNA) sequencing as a non-invasive cancer monitoring method for individuals with HCS.
- The consortium aims to shift cancer surveillance strategies towards more accessible and frequent monitoring, leveraging early detection opportunities identified through their research on commonly characterized HCSs like hereditary breast and ovarian cancer and Lynch syndrome.
ASO Author Reflections: Sentinel Lymph Node Biopsy in BRCA1/2 Germline Pathogenic Variant Carriers Undergoing Risk-Reducing Mastectomy.
Ann Surg Oncol
October 2022
Department of Surgery, McGill University Medical School, Montreal, QC, Canada.
Surgical Management and Contralateral Breast Cancer Risk in Women with History of Radiation Therapy for Hodgkin Lymphoma: Results from a Population-Based Cohort.
Ann Surg Oncol
October 2022
Department of Surgery, McGill University Medical School, Montreal, QC, Canada.
Background: Women with history of chest irradiation for Hodgkin lymphoma are at increased risk of developing bilateral breast cancer, although contralateral breast cancer risk estimates in this population remain undefined.
Methods: We queried the SEER database for women treated with radiation therapy for Hodgkin lymphoma prior to age 30 years and were diagnosed with a subsequent breast cancer between 1990-2016. Trends in surgical management and the 5- and 10-year cumulative incidence of contralateral breast cancer were evaluated.
Background: This study sought to determine the likelihood of occult malignancy during risk-reducing mastectomy in high-penetrance pathogenic variant carriers to help refine axillary staging recommendations.
Methods: The authors performed a retrospective cohort study analyzing all female carriers of pathogenic variants in BRCA1/2, PALB2 or other genes who underwent prophylactic surgery at their institution between 2006 and 2021. Occult breast cancer was defined as the unanticipated presence of in situ or invasive malignancy on pathologic evaluation of prophylactic mastectomy specimens.